Literature DB >> 17639172

Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan, revised 2006.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17639172

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN： 1684-1182            Impact factor:   4.399


× No keyword cloud information.
  4 in total

Review 1.  Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.

Authors:  Gwan-Han Shen; Thomas Chang-Yao Tsao; Shang-Jyh Kao; Jen-Jyh Lee; Yen-Hsu Chen; Wei-Chung Hsieh; Gwo-Jong Hsu; Yen-Tao Hsu; Ching-Tai Huang; Yeu-Jun Lau; Shih-Ming Tsao; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2012-01-28       Impact factor: 5.283

2.  Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial.

Authors:  Chao Zhuo; Yijiang Huang; Wenyuan Liu; Jin-Fu Xu; Wei Yun Zhu; Gregory G Stone; Jean Li Yan; Naglaa Mohamed
Journal:  Infect Drug Resist       Date:  2022-02-23       Impact factor: 4.003

3.  Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia: A Nationwide Population-Based Cohort Study.

Authors:  Chi-Chuan Wang; Chia-Hui Lin; Kuan-Yin Lin; Yu-Chung Chuang; Wang-Huei Sheng
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

Review 4.  Community-Acquired Pneumonia in the Asia-Pacific Region.

Authors:  Jae-Hoon Song; Kyungmin Huh; Doo Ryeon Chung
Journal:  Semin Respir Crit Care Med       Date:  2016-12-13       Impact factor: 3.119
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.